qDSA Blood Flow Measurement in Patients Undergoing TAE of the Liver
Status
Conditions
Treatments
Study type
Funder types
Identifiers
Details and patient eligibility
About
The purpose of this research is to evaluate a new technique, quantitative digital subtraction angiography (qDSA), to measure blood flow during liver embolization procedures. Liver transarterial embolization is a way of treating liver tumors by blocking blood flow to it. The qDSA technique could help doctors ensure the blood flow to the tumor is decreased by the right amount by calculating blood flow before, during, and after the procedure. Up to 20 participants will be enrolled for 1 study visit and data collection for up to 6 months.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Give voluntary, written informed consent to participate in this study and willing to comply with study-related evaluation and procedure schedule
Exclusion criteria
- Pregnancy or breastfeeding
- Patients with an acute kidney injury or stage IV or V chronic kidney disease (Cr greater than 2.4 or estimated glomerular filtration rate (eGFR) less than 30), unless anuric and on dialysis without expected return of renal function.
- Patients with an iodinated contrast allergy who cannot be adequately premedicated to receive contrast as part of the embolization procedure.
- Patients with a physical or psychological condition that would impair study participation.
- The patient is judged unsuitable for study participation by the Investigator for any other reason
Trial design
Primary purpose
Allocation
Interventional model
Masking
20 participants in 1 patient group
Trial contacts and locations
Loading...
Central trial contact
Radiology Coordinators
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal